Groupon Inc. (NASDAQ:GRPN) Director Bradley A. Keywell unloaded 500,000 shares of the company’s stock on the open market in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $7.01, for a total value of $3,505,000.00. Following the sale, the director now directly owns 42,043 shares in the company, valued at approximately $294,721. Groupon, Inc. (NASDAQ:GRPN) in last trading activity decreased -1.74% to close at $7.89. Company weekly performance is 9.74% while its quarterly performance stands at 19.91%. Groupon, Inc. (NASDAQ:GRPN) is -36.47% away from its 52 week high.
The Board of Directors of Annaly Capital Management, Inc. (NYSE:NLY) declared the fourth quarter 2014 common stock cash dividend of $0.30 per common share. This dividend is payable January 29, 2015, to common shareholders of record on December 31, 2014. The ex-dividend date is December 29, 2014.On last trading day Annaly Capital Management, Inc. (NYSE:NLY) decreased -0.44% to close at $11.21. Its volatility for the week is 1.18% while volatility for the month is 1.20%. NLY’s sales growth for past 5 years was 14.00% and its EPS growth for past 5 years was 42.30%. Annaly Capital Management, Inc. (NYSE:NLY) monthly performance is -2.94%.
Frontline Ltd. (NYSE:FRO) on 16 December announced that it has entered into a private agreement to exchange $22,500,000 of the outstanding principal amount of the Company`s 4.5% Convertible Bond Issue 2010/2015 (the “Bonds”) for an aggregate of 3,984,375 shares at an exchange price of $3.12 per share, and a cash payment of $9,562,500 plus accrued interest.On last trading day Frontline Ltd. (NYSE:FRO) decreased -0.41% to close at $2.43. Its volatility for the week is 8.22% while volatility for the month is 8.92%. FRO’s sales growth for past 5 years was -24.50% and its EPS growth for past 5 years was -17.70%. Frontline Ltd. (NYSE:FRO) monthly performance is 82.71%.
On December 12, 2014, Array BioPharma, Inc. (NASDAQ:ARRY) entered into a License Agreement (the “License Agreement”) with Oncothyreon Inc. (“Oncothyreon”). Pursuant to the License Agreement, Array has granted Oncothyreon an exclusive license to develop, manufacture and commercialize ONT-380, an orally active, reversible and selective small-molecule HER2 inhibitor. The License Agreement replaces and terminates the prior Development and Commercialization Agreement under which Oncothyreon and Array were jointly developing ONT-380, and going forward, Oncothyreon will be solely responsible for all pre-clinical and clinical development, regulatory and commercialization activities relating to ONT-380. Array BioPharma, Inc. (NASDAQ:ARRY) has 16.47% insider ownership while its institutional ownership stands at 93.40%. In last trading activity company’s stock closed at $4.64.
Sonic Automotive (NYSE:SAH) has received a “BB-” credit rating from Morningstar. The firm’s “BB-” rating indicates that the company is an above-average default risk. They also gave their stock a three star rating. On Wednesday shares of Sonic Automotive Inc. (NYSE:SAH) closed at $27.32. Company’s sales growth for last 5 years was 5.10% and EPS growth for next 5 years is recorded as 10.50%.